ArticleCureus2026
Evaluating the Efficacy of Brensocatib in Non-cystic Fibrosis Bronchiectasis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiectasis is a widely recognised chronic respiratory illness classified in severity by frequency of exacerbations within the past year, percent predicted forced expiratory volume in 1 second (%FEV1), previous hospital admissions and radiological severity, among other factors. The physiological process is understood to be driven by neutrophilic inflammation and subsequent bronchial wall destruction and dilatation. Brensocatib has emerged as a novel adjunct in the management of chronic bronchiectasis as a dipeptidyl peptidase-1 inhibitor, directly targeting the inflammatory process. The editorial aims to review the mechanism of action of brensocatib, current literature surrounding its efficacy and side effect profile, and potential implications of a wider rollout of the medication to the adult UK population. Whilst the current literature does support a modest reduction in the frequency of exacerbations for patients who trialled bresnocatib, there is a large amount of uncertainty regarding long-term safety, implementation into the current regime, and cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.